» Articles » PMID: 32440702

Evidence of Distinct α-synuclein Strains Underlying Disease Heterogeneity

Overview
Specialty Neurology
Date 2020 May 23
PMID 32440702
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Synucleinopathies are a group of neurodegenerative disorders caused by the misfolding and self-templating of the protein α-synuclein, or the formation of α-synuclein prions. Each disorder differs by age of onset, presenting clinical symptoms, α-synuclein inclusion morphology, and neuropathological distribution. Explaining this disease-specific variability, the strain hypothesis postulates that each prion disease is encoded by a distinct conformation of the misfolded protein, and therefore, each synucleinopathy is caused by a unique α-synuclein structure. This review discusses the current data supporting the role of α-synuclein strains in disease heterogeneity. Several in vitro and in vivo models exist for evaluating strain behavior, however, as the focus of this article is to compare strains across synucleinopathy patients, our discussion predominantly focuses on the two models most commonly used for this purpose: the α-syn140*A53T-YFP cell line and the TgM83 mouse model. Here we define each strain based on biochemical stability, ability to propagate in α-syn140-YFP cell lines, and incubation period, inclusion morphology and distribution, and neurological signs in TgM83 mice.

Citing Articles

Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species.

Sirerol-Piquer M, Perez-Villalba A, Duart-Abadia P, Belenguer G, Gomez-Pinedo U, Blasco-Chamarro L Mol Neurodegener. 2025; 20(1):26.

PMID: 40038767 PMC: 11881471. DOI: 10.1186/s13024-025-00816-1.


Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA.

Heras-Garvin A, Fellner L, Granata R, Wenning G, Stefanova N J Neural Transm (Vienna). 2025; .

PMID: 39954078 DOI: 10.1007/s00702-025-02892-5.


Tracing TMEM106B fibril deposition in aging and Parkinson's disease with dementia brains.

Zhao W, Fan Y, Zhao Q, Fan Z, Zhao J, Yu W Life Med. 2025; 3(1):lnae011.

PMID: 39872397 PMC: 11749594. DOI: 10.1093/lifemedi/lnae011.


In Vitro Cell Model Investigation of Alpha-Synuclein Aggregate Morphology Using Spectroscopic Imaging.

Swaminathan P, Klingstedt T, Theologidis V, Gram H, Larsson J, Hagen L Int J Mol Sci. 2024; 25(22).

PMID: 39596523 PMC: 11594916. DOI: 10.3390/ijms252212458.


α-Synuclein seeding amplification assays for diagnosing synucleinopathies: an innovative tool in clinical implementation.

Kuang Y, Mao H, Huang X, Chen M, Dai W, Gan T Transl Neurodegener. 2024; 13(1):56.

PMID: 39574205 PMC: 11580393. DOI: 10.1186/s40035-024-00449-2.


References
1.
Ahmed Z, Asi Y, Sailer A, Lees A, Houlden H, Revesz T . The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol. 2011; 38(1):4-24. DOI: 10.1111/j.1365-2990.2011.01234.x. View

2.
Asante E, Grimshaw A, Smidak M, Jakubcova T, Tomlinson A, Jeelani A . Transmission Properties of Human PrP 102L Prions Challenge the Relevance of Mouse Models of GSS. PLoS Pathog. 2015; 11(7):e1004953. PMC: 4489887. DOI: 10.1371/journal.ppat.1004953. View

3.
Atsmon-Raz Y, Miller Y . A Proposed Atomic Structure of the Self-Assembly of the Non-Amyloid-β Component of Human α-Synuclein As Derived by Computational Tools. J Phys Chem B. 2015; 119(31):10005-15. DOI: 10.1021/acs.jpcb.5b03760. View

4.
Ayers J, Brooks M, Rutherford N, Howard J, Sorrentino Z, Riffe C . Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils. J Virol. 2016; 91(2). PMC: 5215322. DOI: 10.1128/JVI.02095-16. View

5.
Ayers J, Riffe C, Sorrentino Z, Diamond J, Fagerli E, Brooks M . Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts. J Virol. 2018; 92(18). PMC: 6146706. DOI: 10.1128/JVI.00586-18. View